HLA associations with nasopharyngeal carcinoma.
Several associations have been described between the frequency of human leukocyte antigen (HLA) class I genes in certain populations and the risk of developing nasopharyngeal carcinoma (NPC). Associations between ethnic background and geographic distribution, and relative disease incidence have been reported. Populations in geographical areas at higher risk of developing NPC display HLA distribution patterns different and sometimes opposite from areas of low incidence, whereas populations in areas with intermediate incidence display a totally independent pattern. Two main reasons may explain this association between HLA phenotype distribution and the risk of developing NPC in various populations. First, given the fact that expression of Epstein-Barr Virus (EBV) proteins by cancer cells is tightly linked with NPC development, HLA may influence the development of NPC by modulating the expression of EBV proteins. This explanation is, however, based primarily on theoretical assumptions given that no clear definition of HLA binding pattern of EBV epitopes has been directly shown to significantly alter the recognition of EBV proteins and the risk of developing the disease. Alternatively, HLA may represent a genetic marker flagging the presence of a NPC predisposition locus in close linkage disequilibrium with the HLA class I region. A critical review of known HLA associations in various geographical areas and their interpretation will be presented in this review.
Li
Xin
X
Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA. xinli268@gmail.com
Fasano
Ross
R
Wang
Ena
E
Yao
Kai-Tai
KT
Marincola
Francesco M
FM
D000483:Alleles; D005843:Geography; D006680:HLA Antigens / Q000276:immunology*; D006801:Humans; D009303:Nasopharyngeal Neoplasms / Q000453:epidemiology / Q000235:genetics / Q000276:immunology*; D015995:Prevalence; D012307:Risk Factors
D006680:HLA Antigens
J Immunol. 1997 Apr 1;158(7):3325-34
9120290
Tissue Antigens. 2007 Apr;69 Suppl 1:237-40
17445209
Leukemia. 2004 Dec;18(12):2002-7
15470487
Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1100-4
14578150
Clin Otolaryngol Allied Sci. 2002 Feb;27(1):61-7
11903375
J Exp Med. 2004 Jul 5;200(1):13-24
15226359
Singapore Med J. 2007 Jul;48(7):632-4
17609824
Br J Cancer. 1985 Mar;51(3):389-92
3855643
Tissue Antigens. 1983 Jul;22(1):72-5
6577695
Asian Pac J Cancer Prev. 2005 Jul-Sep;6(3):270-5
16235985
Mol Immunol. 2005 Feb;42(4):557-60
15607813
Oncology. 2001;61(1):55-8
11474249
Tissue Antigens. 1983 Nov;22(5):335-41
6419386
Science. 2004 Aug 6;305(5685):872-4
15297676
Cancer Immunol Immunother. 2005 Feb;54(2):172-8
15248031
World J Gastroenterol. 2006 Jun 21;12(23):3628-35
16773677
Natl Cancer Inst Monogr. 1977 Dec;47:153-6
613234
Br J Cancer. 1995 Feb;71(2):400-8
7841061
J Med Assoc Thai. 2003 Jun;86 Suppl 2:S237-41
12929995
Natl Cancer Inst Monogr. 1977 Dec;47:143-6
613232
Cancer Immunol Immunother. 2007 Jan;56(1):95-100
16547704
Biochem Biophys Res Commun. 2005 Dec 2;337(4):1047-51
16229821
BMC Cancer. 2001;1:4
11389775
Int J Cancer. 1994 Feb 15;56(4):465-7
8112882
Cancer Res. 2006 Jan 15;66(2):693-700
16423998
Anticancer Res. 1989 Nov-Dec;9(6):1649-53
2697183
Immunol Lett. 2000 Jun 1;72(3):179-82
10880839
Int J Cancer. 2005 Jul 10;115(5):742-6
15729690
Tissue Antigens. 2002 Mar;59(3):223-5
12074714
Cancer Epidemiol Biomarkers Prev. 1996 Nov;5(11):879-87
8922295
Int J Cancer. 1975 Aug 15;16(2):249-54
1150352
Panminerva Med. 1983 Oct-Dec;25(4):255-7
6584851
Cancer Res. 2004 Mar 15;64(6):1972-4
15026332
World J Gastroenterol. 2007 Mar 28;13(12):1770-87
17465466
J Virol. 1993 Dec;67(12):7428-35
7693972
Br J Cancer. 1995 Jul;72(1):117-22
7599039
Int J Cancer. 2006 Dec 15;119(12):2821-6
16929489
Science. 1996 Apr 5;272(5258):67-74
8600539
Curr Opin Rheumatol. 2003 Jul;15(4):369-73
12819462
Nature. 1990 Aug 2;346(6283):470-1
2377207
Genet Med. 2006 Mar;8(3):156-60
16540749
Natl Cancer Inst Monogr. 1977 Dec;47:147-51
613233
Eur J Epidemiol. 2005;20(6):475-88
16121756
Blood. 2005 Nov 15;106(10):3666-72
16046526
Cancer Res. 2002 Dec 1;62(23):6952-8
12460912
Br J Cancer. 2005 Mar 14;92(5):967-70
15726104
Hum Immunol. 2000 Jan;61(1):74-81
10658980
Blood. 2007 May 15;109(10):4296-305
17272507
J Gen Virol. 2004 Jul;85(Pt 7):2023-2034
15218188
Eur J Immunol. 1998 Feb;28(2):451-8
9521052
Cancer Res. 1974 May;34(5):1192-5
4842362
Genome Biol. 2006;7 Suppl 1:S13.1-10
16925835
Cancer Epidemiol Biomarkers Prev. 1995 Sep;4(6):607-10
8547826
Int J Cancer. 2003 Mar 1;103(6):745-51
12516093
Int J Cancer. 2001 Apr 15;92(2):294-7
11291059
Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2673-7
16284396
Oncology. 1997 May-Jun;54(3):185-92
9143397
J Clin Immunol. 2006 Jan;26(1):22-32
16418800
Cancer Immunol Immunother. 2007 Jul;56(7):1047-63
17124584
Hum Immunol. 1982 Oct;5(2):91-105
7141899
Cancer Res. 2006 Aug 15;66(16):7999-8006
16912175
Ai Zheng. 2005 Aug;24(8):915-8
16086865
BMC Genet. 2003 Jan 21;4:3
12546713
J Natl Cancer Inst. 2002 Dec 4;94(23):1780-9
12464650
J Mol Med (Berl). 2004 Jul;82(7):414-22
15148580
Curr Opin Immunol. 2004 Oct;16(5):660-7
15342014
Int J Cancer. 2007 Jun 1;120(11):2401-10
17315195
Int J Cancer. 1994 Mar 15;56(6):830-3
7907078
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2002 Apr;19(2):134-7
11941590
Int J Cancer. 1983 Aug 15;32(2):171-6
6874140
J Immunol. 2007 Aug 1;179(3):1625-33
17641029
Ai Zheng. 2002 Jun;21(6):597-600
12452057
Nat Genet. 2002 Aug;31(4):395-9
12118254
Int J Cancer. 1997 Apr 22;74(2):229-32
9133461
IARC Sci Publ (1971). 1975;(11 Pt 2):249-58
191368
J Transl Med. 2007 May 04;5:22
17480220
Cancer Lett. 2003 Apr 10;193(1):75-81
12691826
Hum Genomics. 2006 Jun;2(6):365-75
16848974
J Biomed Sci. 2005 Dec;12(6):925-36
16307312
Mol Interv. 2005 Aug;5(4):226-40
16123537
Cancer Epidemiol Biomarkers Prev. 1999 Jun;8(6):547-51
10385146
Leukemia. 2007 Oct;21(10):2145-52
17673900
Nat Genet. 2007 Jun;39(6):733-40
17496894
Sci China C Life Sci. 2007 Apr;50(2):203-11
17447027
Genome Res. 2007 Jun;17(6):839-51
17568002